Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | AGL | P35573 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870963 | 1.00 | GBA1 (0.55) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL13966629 | 1.00 | GBA1 (0.55) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL13966630 | 1.00 | GBA1 (0.55) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL6248843 | 0.88 | GBA1 (0.52) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL8108717 | 0.88 | GBA1 (0.52) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL7919080 | 0.88 | GBA1 (0.52) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL9205719 | 0.88 | GBA1 (0.52) | GBA1SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL31469245 | 0.78 | GBA1 (0.77) | GBA1SLC18A3SIGMAR1TSHRMEN1 | |
| SCHEMBL17881901 | 0.78 | GBA1 (0.77) | GBA1SLC18A3SIGMAR1TSHRMEN1 | |
| SCHEMBL19471082 | 0.78 | GBA1 (0.77) | GBA1SLC18A3SIGMAR1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
| CN-107108492-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-10092529-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-09 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304237-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | GBA1 2077/4885SLC18A3 4885/4885SIGMAR1 1517/4885 |
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | GBA1 2337/4885SLC18A3 4882/4885SIGMAR1 1782/4885 |
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | GBA1 2337/4885SLC18A3 4882/4885SIGMAR1 1782/4885 |
| US-10092529-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | GBA1 2077/4885SLC18A3 4885/4885SIGMAR1 1517/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | GBA1 2337/4885SLC18A3 4882/4885SIGMAR1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.